Olema Pharmaceuticals
OLMA
87 hedge funds and large institutions have $329M invested in Olema Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 21 increasing their positions, 23 reducing their positions, and 13 closing their positions.
181% more capital invested
Capital invested by funds: $117M → $329M (+$212M)
169% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 13
34% more funds holding
Funds holding: 65 → 87 (+22)
33% more call options, than puts
Call options by funds: $370K | Put options by funds: $278K
7.09% more ownership
Funds ownership: 82.24% → 89.34% (+7.1%)
9% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.39M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$8.14M |
| 3 |
BlackRock
New York
|
+$8.07M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$3.55M |
| 5 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$7.28M |
| 2 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$4.27M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.59M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$2.11M |
| 5 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.1M |
OLMA Hedge Fund Activity: Q2 2023 in Review
87 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q2 2023, worth a combined $329M — up 181% from $117M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new OLMA positions and 13 closed out — a net gain of 22 holders — while 21 added to existing stakes and 23 trimmed.
The largest buyer was Dimensional Fund Advisors, adding an estimated $8.39M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $7.28M sold.
- 87 institutional investors held Olema Pharmaceuticals (OLMA) as of Q2 2023, up from 65 in Q1 2023.
- Funds reported $329M of Olema Pharmaceuticals stock for Q2 2023, up 181% quarter-over-quarter.
- 35 funds opened new Olema Pharmaceuticals positions in Q2 2023 and 13 closed out, a net change of +22 holders.
- The largest Olema Pharmaceuticals buyer in Q2 2023 was Dimensional Fund Advisors, an estimated $8.39M added.
- The largest Olema Pharmaceuticals seller in Q2 2023 was Janus Henderson Group, an estimated $7.28M sold.
Based on aggregated 13F filings for Q2 2023.